Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti - 1 Jan 2000

Büchler Tomáš, Bobek Vladimír, Kološtová Katarína

Abstract excerpt

BACKGROUND: Several systemic treatment options are currently available for patients with metastatic castration-refractory prostate cancer (mCRPC), including the androgen-receptor targeting agents (ARTA) enzalutamide and abiraterone, the taxanes docetaxel and cabazitaxel, and the radioisotope drug 223-radium dichloride. In some patients with mCRCP, alternative splicing of androgen receptor (AR) mRNA occurs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androstenes
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzamides

Share to Biomarkers, Tumor

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Treatment Outcome

Source

Identifiers

PMID: 29488772
DOI: 10.14735/amko20189

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].PMID 29488772Read ↗

Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer: A critical review.Semantic proximity Read ↗

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.Semantic proximity Read ↗

AR Splicing Variants and Resistance to AR Targeting AgentsSemantic proximity Read ↗

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Semantic proximity Read ↗

Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancerSemantic proximity Read ↗

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].Semantic proximity Read ↗

Assessment of Androgen Receptor splice variant-7 as a biomarker of clinical response in castration-sensitive prostate cancerSemantic proximity Read ↗

AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption.Semantic proximity Read ↗

Prognostic Role of Androgen Receptor Splice Variant 7 (AR-V7) in the Pathogenesis of Breast CancerSemantic proximity Read ↗

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.Semantic proximity Read ↗

The Clinicopathological Characteristics of Androgen Receptor Splicing Variant 7 (AR-V7) Expression in Patients with Castration Resistance Prostate Cancer: A Systematic Review and Meta‐AnalysisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.